Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, says initial analysis of the first 13 patients enrolled in the MVI-118 clinical trial shows acceptable safety and tolerability, and enhanced patient immune response to the AR antigen encoded by the vaccine. The human androgen receptor is the critical biological target that drives the progression of prostate cancer and, in many cases, is responsible for the resistance to current therapies. MVI-118 is being developed to prolong the duration of disease control gained from standard hormone deprivation therapies. The findings will be presented at the annual Prostate Cancer Foundation Scientific Retreat, October 27, in Carlsbad, CA, just north of San Diego.
Read more at MadisonVaccinesInc.com.